NASDAQ · FBIO
Fortress Biotech, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for FBIO: Nov 13, 2026
Fortress Biotech, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $0.11.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · MarketBeat · RTTNews · NASDAQ.com- The Motley Fool · Aug 13, 10:28 PM EDTFortress Biotech (FBIO) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 12, 7:04 PM EDTFortress Biotech Q2 Earnings Call HighlightsJourney Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief Executive Officer Claude Maraoui said the company generated positive EBITDA in the
- RTTNews · Mar 31, 4:31 AM EDTCyprium Therapeutics Closes Sale Of Rare Pediatric Disease PRV For $205 Mln(RTTNews) – Fortress Biotech, Inc. (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, Inc., on Monday announced the closing of the sale of Cyprium's Rare Pediatric Disease Priority Review Voucher or PRV for gross proceeds of $205 million.
- NASDAQ.com · Mar 25, 2:00 PM EDTAfter-Hours Earnings Report for March 25, 2026 : JEF, CELC, FUL, EPAC, WS, MLKN, PGEN, BYND, MDV, DERM, FBIO, GCTSThe following companies are expected to report earnings after hours on 03/25/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Jefferies Financial Group Inc. (JEF)is reporting for the quarter ending February 28, 2026. The financial services company'
- RTTNews · Feb 23, 10:12 AM ESTFortress Biotech's Cyprium To Sell $205 Million Priority Review Voucher; Shares Rise(RTTNews) – Fortress Biotech, Inc. (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, Inc., announced that Cyprium has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million, subject to
- RTTNews · Feb 23, 10:12 AM ESTFortress Biotech's Cyprium To Sell $250 Million Priority Review Voucher; Shares Rise(RTTNews) – Fortress Biotech, Inc. (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, Inc., announced that Cyprium has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million, subject to
- Zacks · Feb 5, 12:56 PM ESTCigna Q4 Earnings Beat Estimates on Higher Specialty VolumesCI's Q4 adjusted EPS beats estimates as Evernorth growth and higher specialty volumes offset fewer medical customers and elevated costs.
- Zacks · Jan 28, 12:21 PM ESTElevance Health Q4 Earnings Beat Estimates on Increasing PremiumsELV tops Q4 EPS estimates as premiums grow and Carelon revenues surge, even as medical membership slips and expenses climb.
- Zacks · Jan 21, 1:29 PM ESTCentene Expands Palliative Care Access in Ohio Through Tuesday HealthCNC teams up with Tuesday Health to expand palliative care in Ohio, blending in-person and virtual support.
- RTTNews · Jan 16, 8:58 AM ESTWeekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch(RTTNews) – This week, the biotech sector saw a steady stream of high-impact news, including a major workforce reduction and a fresh round of regulatory clearances spanning diabetes, rare diseases, biosimilars, and women's health technologies.
- RTTNews · Jan 13, 9:18 AM ESTFortress Biotech Announces FDA Approval For ZYCUBO, First Treatment For Menkes Disease In The U.S.(RTTNews) – Fortress Biotech, Inc. (FBIO) and its majority-owned subsidiary Cyprium Therapeutics have received U.S. FDA approval for ZYCUBO, the first and only approved treatment for Menkes disease in the United States.
- RTTNews · Jan 13, 9:01 AM ESTFortress Biotech Announces FDA Approval Of ZYCUBO For Pediatric Menkes Disease(RTTNews) – Fortress Biotech, Inc. (FBIO) and its majority-owned subsidiary, Cyprian Therapeutics, Inc., on Tuesday said the U.S. Food and Drug Administration has approved ZYCUBO for the treatment of Menkes disease in pediatric patients. Until now, there has been no approved trea
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Fortress Biotech, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.